A conventional replication-incompetent adenovirus (Ad) vector exhibits the leaky expression of Ad genes following transduction, leading to an induction of cellular immunity against Ad proteins and Ad protein-induced toxicity. In order to suppress the leaky expression of Ad genes, we developed novel Ad vectors by incorporating four tandem copies of sequences with perfect complementarity to miR-122a or miR-142-3p, which exhibits liver-, or spleen-specifi c expression, respectively, into the 3'-untranslated region (UTR) of the E2A, E4, or pIX gene (Shimizu K. et al., ASGCT annual meeting 2012) . These Ad vectors easily grew to high titers comparable to those of a conventional Ad vector in normal 293 cells. The leaky expression of these Ad vectors in mouse organs (liver and spleen) was signifi cantly suppressed by 2-to 100-fold, compared with a conventional Ad vector, by insertion of the miRNA-targeted sequences. Notably, the Ad vector carrying the miR-122a-targeted sequences into the 3'-UTR of the E4 gene (Ad-E4-122aT) expressed about 100-fold lower levels of all the Ad early and late genes examined in the liver than a conventional Ad vector. Furthermore, Ad-E4-122aT mediated approximately 2-to 4-fold lower levels of serum alanine aminotransferase (ALT) levels, compared with a conventional Ad vector. However, the numbers of CTL against the hexon, which is the dominant epitope of Ad vector, in the splenocytes were not signifi cantly different between the Ad vectors examined. Numbers of T-cells infi ltrated in the liver following intravenous administration were comparable between the mice treated with a conventional Ad vector and those treated with Ad-E4-122aT. These results indicate that insertion of miR-122atargeted sequences into the E4 gene 3'-UTR did not reduce the immune responses to Ad proteins. In order to examine whether Ad vector-induced hepatotoxicity via immune-independent pathway was suppressed by insertion of miR-122a-targeted sequences into the E4 gene 3'-UTR, Ad vectors were administered to the immuneincompetent mice (Rag2/IL2Rc knockout mice). The conventional Ad vector signifi cantly elevated the serum ALT levels following administration, on the other hand, no increases in the serum ALT levels were found in Ad-E4-122aT-treated immune-incompetent mice.
These results indicate that miR-122a-mediated suppression of the E4 gene expression in the liver signifi cantly reduced the hepatotoxicity which an Ad vector causes via non-immunological pathway, and that Ad-E4-122aT would be a valuable vector for safe and effective gene therapies and basic researches.
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One of the fi rst fi ber-chimeric adenovirus (Ad) vectors generated, contained the tail and long fi ber shaft of Ad5 and the fi ber knob domain of Ad3 (Ad5/3L). This tropism-modifi ed vector has been shown to efficiently transduce cancer cells. Oncolytic vectors possessing Ad5/3L capsids have been used in clinical trials by several groups. We recently identifi ed human desmoglein 2 (DSG2) as a new Ad receptor and showed that Ad5/3L uses DSG2 in in vitro transduction studies. Because the mouse orthologue of DSG2 cannot function as a receptor for Ad5/3L, biodistribution studies in mice were so far of limited value. We have therefore generated transgenic mice that express human DSG2 in a pattern and at a level comparable to humans. Furthermore, we modifi ed a syngeneic epithelial tumor cell line to overexpress human DSG2 (TC1-DSG2). For biodistribution studies we produced vectors with different capsids that expressed fi refl y luciferase under the control of the CMV promoter. Two vectors were based on Ad5 and either contained the long Ad5 fi ber shaft and the Ad3 fi ber knob (Ad5/3L) or the short Ad3 fi ber shaft and knob (Ad5/3S). In vitro, both Ad5/3L and Ad5/3S vectors transduced cells with similar effi cacy in a DSG2-dependent manner. For in vivo studies, we used DSG2-transgenic mice with TC1-DSG2 tumors and non-transgenic littermates with TC1 tumors. We injected the luciferase expressing Ad5/3 vectors intravenously and studied transgene expression three days later. Non-invasive in vivo imaging of luciferase expression revealed strong signals for Ad5/3L in the liver for both, DSG2-transgenic and non-transgenic animals. DSG2-independent liver transduction is most likely mediated through the Ad5 hexonfactor X pathway. Importantly, DSG2-transgenic mice, but not DSG2negative mice showed signals in subcutaneous tumors, indicating DSG2-dependent transduction. No specifi c signals were detected in mice injected with Ad5/3S by in vivo imaging. Measurements of luciferase activity in tissue homogenates corroborated DSG2independent liver transduction and DSG2-dependent transduction of tumor. In addition we found luciferase expression form Ad5/3L in the gastro-intestinal tract of DSG2 transgenic mice. Luciferase activity in the liver was 2-3 logs lower with Ad5/3S indicating that the Ad5 hexon-factor X pathway is not effi cient for short-shafted Ad vectors such as Ad5/3S. Luciferase immunoreactivity was found in the small intestine and colon in lamina propria macrophages as well as in intestinal epithelial cells. We also attempted to generate a luciferase vector that was entirely based on Ad serotype 3. During virus propagation in HeLa cells, we noticed however undesired rearrangements in the Ad3-luciferase viral genome. We are therefore currently re-designing the vector. Biodistribution data with the Ad3luciferase vector will be reported. Our fi ndings have implications for assessing the safety profi le of Ad5/3 vectors and reveal insights into determinants of in vivo tropism of these vectors.
